[Recurrent dysregulation of body temperature during antipsychotic pharmacotherapy].
OBJECTIVE
This case report presents a rare, potentially life-threatening vegetative disturbance, which can occur during pharmacotherapy of schizophrenia.


METHODS
A retrospective descriptive transversal and longitudinal section consideration of in-patient treatments of one female was performed.


RESULTS
A 50-years old woman suffering from oligophrenia and disorganized psychosis (ICD-10: F71, F20.1; DSM-IV: 318, 295.10) successively evolved hypothermias up to 32.0 degrees C rectal, between them fever up to 40.0 degrees C rectal, hypothermia-accompanied bradycardias up to 32/min, recurrent subclinical hypoglycaemias up to 55 mg/dl and somnolence until coma under benperidol with levomepromazine or melperone, pipamperone with and without amisulpride, promethazine as well as zuclopenthixole. Within hours the hypothermias responded to antipsychotic drug holiday. No pathbreaking finding could be ensured on levels of internal medicine, toxicology, neurology as well as neurophysiology including a transient aetiologically uncertain partial insufficiency of the adenohypophysis.


CONCLUSIONS
During long-term treatment with antipsychotics especially in higher dosage unpredictable vegetative crises may occur. Antipsychotics having pronounced 5HT2- and D2-antagonism seem to be rather associated with hypothermia. We recommend in case of hypothermia below 35,5 degrees C immediate antipsychotic or anticholinergic drug discontinuation, usage of benzodiazepines like lorazepam for a few days and a following trial with ziprasidone, aripiprazole or clozapine. These atypical neuroleptics show receptor binding profiles potentially advantageous in hypothermia.
Löffler
Stefan
S
Klinik für Psychiatrie und Psychotherapie, Klinikum Offenbach GmbH, Akademisches Lehrkrankenhaus der Johann Wolfgang Goethe-Universität Frankfurt am Main. stefan.loeffler@klinikum-offenbach.de
Danos
Peter
P
Schillen
Thomas B
TB
Klimke
Ansgar
A
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001833:Body Temperature Regulation / Q000187:drug effects*; D001919:Bradycardia / Q000139:chemically induced / Q000628:therapy; D003128:Coma / Q000139:chemically induced / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000628:therapy; D007035:Hypothermia / Q000139:chemically induced*; D008607:Intellectual Disability / Q000188:drug therapy*; D008134:Long-Term Care; D008875:Middle Aged; D012008:Recurrence; D012562:Schizophrenia, Disorganized / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000628:therapy
D014150:Antipsychotic Agents